Back to Search
Start Over
Weekly cisplatin plus capecitabine in metastatic breast cancer patients heavily pretreated with both anthracycline and taxanes
- Source :
- Oncology. 69(5)
- Publication Year :
- 2005
-
Abstract
- Background: Treating patients with anthracycline- and taxane-pretreated metastatic breast cancer is challenging. This study evaluated the activity and safety of a combination of cisplatin and capecitabine in this setting. Patients and Methods: Thirty-nine consecutive patients entered the study. All had experienced failures or relapse after previous treatment with anthracyclines and taxanes plus/minus other chemotherapeutic regimens. The present treatment consisted of intravenous cisplatin 20 mg/m2 every week for 6 weeks, followed by 1 week of rest, and oral capecitabine 1,000 mg/m2 twice daily for 14 days, followed by a 7-day rest period. Results: Objective response was obtained in 14 patients (35.9%), with complete remission in 3 (7.7%). Median time to progression was 5.2 months and survival was 10.9 months in the entire population and 8.7 and 16.5 months in the responding patients, respectively. The dose-limiting toxicity for the regimen was leucopenia, while gastrointestinal discomfort was the most frequent cause of capecitabine reduction or delay. Conclusions: The cisplatin and capecitabine combination regimen is active and manageable. It seems to be non-cross resistant to anthracyclines and taxanes.
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Time Factors
Anthracycline
Transcription, Genetic
Green Fluorescent Proteins
Antigen-Presenting Cells
HLA-A24 Antigen
Breast Neoplasms
Enzyme-Linked Immunosorbent Assay
Deoxycytidine
Metastasis
Capecitabine
Interferon-gamma
Breast cancer
Genes, Reporter
Internal medicine
Weekly cisplatin
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Anthracyclines
RNA, Messenger
Neoplasm Metastasis
Cisplatin
Taxane
HLA-A Antigens
business.industry
Remission Induction
General Medicine
Dendritic Cells
medicine.disease
Flow Cytometry
Metastatic breast cancer
Treatment Outcome
Microscopy, Fluorescence
Disease Progression
Leukocytes, Mononuclear
Taxoids
Fluorouracil
Immunotherapy
Anthracycline Taxane Capecitabine Cisplatin Metastatic breast cancer
business
medicine.drug
Subjects
Details
- ISSN :
- 00302414
- Volume :
- 69
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Oncology
- Accession number :
- edsair.doi.dedup.....dae855e3db132d5bd29d0442fb58cef8